More on VKTX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $34.81 |
|
|||
| Open | $35.63 | ||||
| 52 Wk High | $5.17 | ||||
| 52 Wk Low | $0.94 | ||||
| Day High | $38.08 | ||||
| Day Low | $35.03 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 4,654,355 | ||||
- Viking Therapeutics starts Phase 1 trial of weight loss drug VK3019
- Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
- Viking Therapeutics names Hubert Chen as chief medical officer
- Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
- Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows
- Form 4 Viking Therapeutics, For: Jun 01 Filed by: Chen Hubert C
- Form 3 Viking Therapeutics, For: Jun 01 Filed by: Chen Hubert C
- Lake Street Starts Viking Therapeutic (VKTX) at Buy
- Truist Securities Assumes Viking Therapeutic (VKTX) at Buy
- Form 8-K Viking Therapeutics, For: May 19
Entities mentioned with VKTX
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- FDA | View Related Stories »
- William Blair | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Show More...
